Get started
PIRAMAL ENTERPRISES LTDPIRAMAL ENTERPRISES LTDPIRAMAL ENTERPRISES LTD

PIRAMAL ENTERPRISES LTD

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options Bonds

PEL trade ideas

PEL { Short 15 M }W frame resistance : breaking doji in 15 m tf intraday Do as mentioned Note :- Entry - At the break of mentioned candle's low/high Stop Loss - In a Short Trade, I always use Previous Candle High ( PCH ) as a stop loss while entering the trade. Sometime I might use smaller tf SL & trade in 15M or 30M tf which I'll mention. Vice Versa for long trades Trailing Stop Loss ( TSL ) - Mostly I trail stop loss by PCH as price falls . I exit as PCH breaks & vice versa Use of PSAR indicator as TSL :- TSL get's hit in trend following due to noise, In such cases I use PSAR to be in trend & exit if PSAR direction change ( PSAR : Parabolic Stop n reverse ) You can use any one of above mentioned or your own way to manage risk Time Frame :- I take ~ 90% of my intraday trades in 15m tf. Where my analysis might come from higher frames like W , D or 1hr chart pattern which will be mentioned. Target :- I do set target line based on support / resistance slightly above/ below it . Please pay attention to it
NSE:PELShort
by ShivamMendhare
The overall outlook for Piramal Enterprises (NS:PIRA) Ltdthe daily chart, PEL ltd is moving in an impulse wave pattern. Wave 4 is completed near 1600 levels and now wave 5 is in progress. The stock had finally given breakout over its consolidation phase. Ichimoku cloud has given the indication of positive strength as prices have broken above the cloud in the previous trading session. as buying opportunity for a movrds 1850 and then 1890 levels as long as we seen At 2180.... Disclaimer: this is not SEBI Registered Investment Advisor, Investing and Trading in the stock market is subject to market risk.
NSE:PELLong
by tradingjourney21
1
pel Piramal Enterprise Limited (PEL) is one of India's large diversified companies with presence in Pharma, Financial Services and Healthcare Information Management. The Company's pharmaceutical business consists of manufacturing and sale of own and traded bulk drugs and formulations. Its Healthcare segment includes pharma solutions, critical care, consumer products and imaging. Its Financial Services segment includes wholesale lending, alternative asset management and investments in Shriram Group. Its Information Management segment is engaged in Decision Resources Group (DRG). DRG's product and services portfolio consists of data and analytics, research products and global consulting services. The Company offers its products under brands, including Saridon, Lacto Calamine, i-pill/i-know, Polycrol, Tetmosol, Untox, Stop AllerG and Throatsil. Over the last 2 years, the company has raised ~₹18,000 crore of equity as a result of which, its equity base increased by 29% and the net debt reduced by 45%. • It had an unallocated equity of ₹11,029 crore as on 31st March, 2021, which included investments in Shriram. • It also raised ₹33,478 crore of long term borrowings in the last 2 years which was utilized to repay most of its short term commercial paper borrowings. • It had a cash balance of ₹7,025 crore as on 31st March, 2021 which is ~15% of its loan book size. • The DHFL acquisition remains on track. It received the RBI (Reserve Bank of India) approval in February, 2021 and also the approval from the Competition Commission of India (CCI) was received in April, 2021. It is expected to be completed in the next few months. • DHFL acquisition fits well into the company’s overall retail strategy as it will enable it to achieve scale and leverage in the platform to cross-sell, significantly change its loan mix and lower its cost of borrowings. • The company is progressing towards transforming itself from a largely wholesale led NBFC (nonbanking financial companies) mostly focused on real estate, to a well-diversified one with the share Concall Summary PIRAMAL ENTERPRISES LIMITED of retail at 50% of the lending book in the near term from 12% as of March, 2021. This is done by undertaking three major strategies: Organic build-up of the retail lending business, completion of the DHFL acquisition and rationalising its wholesale portfolio to a more granular one. • During the year, Piramal Pharma Limited raised $490 million of fresh equity capital from the Carlyle Group for a 20% stake at an enterprise value (EV) of $2.7 billion. • In the complex hospital generics space, it completed the acquisition of Navin Flourine’s remaining 49% stake in convergence chemicals. • In Lodha, as on March, 2021, its exposure stood at ₹2,637 crore of which ~₹1,593 crore is in a SPV (special purpose vehicle) with a 1.5 times cover of fully ready inventory and the balance ~₹1,058 crore is in Macrotech Developers. It recently received a prepayment of ₹431 crore in the month of April, 2021, so its combined exposure has reduced to ₹2,150 crore. • In the CDMO business, it announced an investment of $32 million in its Riverview facility. • Real estate sector witnessed a revival in demand since October, 2020 driven by pent up in demand, changing customer preferences and Government initiatives. • Sales in the real estate segment are expected to fall in the month of May but collections for the company shall not be impacted to that extent. • Given the company has a strong order book and a lower base of FY21, the Pharma segment is expected to perform better in FY22. On a long term perspective, the management expects to maintain an organic growth of 15% for this business.
NSE:PELLong
by Tradernawab